SLU-PP-332 - what is it and how does it work?

SLU-PP-332 weight loss supplement is a synthetic compound known to act as an agonist of estrogen-related receptors (ERR), in particular ERRα, ERRβ and ERRγ. It is a real treat for people who dream of a slim figure, but for some reason find it difficult to achieve a low level of body fat.SLU-PP-332 has gained significant interest in the scientific community, as it exhibits the properties of an "exercise mimetic".

This term refers to its ability to pharmacologically induce physiological and metabolic adaptations that closely resemble those achieved through physical exercise, especially endurance or aerobic training.

SLU-PP-332 accomplishes this by activating natural metabolic pathways that are typically involved in response to physical exercise, leading to increased energy expenditure and increased fat metabolism.

Workout without leaving your couch?

Scientific studies suggest that SLU-PP-332 is one of those dietary supplements that activates similar mechanisms to a good quality workout. This means that your body starts all the processes that accompany it during a hard workout! How does this happen? What is the mechanism of action of the active substance? We have described all doubts in the text below.

SLU-PP-332 target - ERR receptors

SLU-PP-332 exerts its effect by targeting estrogen-related receptors (ERR). ERRs play a fundamental role in regulating metabolic genes and maintaining cellular energy homeostasis. ERRα and ERRγ isoforms are particularly abundant in tissues with high energy demands, such as the heart, kidneys, skeletal muscle, brain, and brown adipose tissue.

SLU-PP-332 functions as an ERR agonist, meaning that it activates all three ERR isoforms. Its effects will effectively enhance metabolic changes throughout the body, providing benefits related to improved metabolic function and the ability to use energy efficiently. A key finding is that SLU-PP-332 induces training-like responses in skeletal muscle.

Use of SLU-PP-332 consistently increases energy expenditure. Measurements showed significantly higher resting energy expenditure compared to the control groups. This increased energy expenditure is accompanied by a noticeable change in the use of energy by the whole body, favoring the oxidation of fatty acids over carbohydrates. This metabolic response mimics the patterns of substrate utilization seen during periods of fasting or prolonged aerobic exercise.

Fatty Acid Oxidation

Direct measurements confirm the shift to fat burning. SLU-PP-332 significantly increased the rate of fatty acid oxidation by approximately 25%.

Effects on Body Composition

Increased energy expenditure and fat oxidation translate into significant effects on body composition. SLU-PP-332 effectively reduces overweight and obesity, even without drastic dietary interventions.

Glucose homeostasis and increased insulin sensitivity

In addition to weight control, SLU-PP-332 improves parameters related to glucose control and insulin action, especially in people who have problems with these parameters. The use of SLU-PP-332 led to lower fasting plasma glucose and insulin levels, indicating improved insulin sensitivity. Better glucose tolerance was also demonstrated. Interestingly, healthy people did not experience a decrease in fasting glucose levels, but better glucose uptake by muscle tissue was observed.

SLU-PP-332 - does not suppress appetite

A key aspect that distinguishes SLU-PP-332 from some other weight loss agents, such as GLP-1 receptor agonists, is its mechanism of action involving food intake. Many studies consistently report that the significant weight loss and metabolic benefits induced by SLU-PP-332 occur without any reduction in appetite. The weight loss is therefore not related to a reduction in calorie intake, but to improved metabolic function.

SLU-PP-332 - Effects on the Body's Exercise Capacity

Increased Muscle Endurance

One ​​of the most striking effects of SLU-PP-332 is its ability to significantly increase physical endurance in mice, which strongly supports its designation as an exercise mimetic. In standardized treadmill running tests, SLU-PP-332-treated mice showed remarkable improvements in performance, being able to run approximately 70% longer and cover 45% greater distance before exhaustion compared to vehicle-treated controls.

Muscle Fiber Activity Changes

Consistent with the adaptations observed during endurance training, SLU-PP-332 treatment promotes a shift in skeletal muscle fiber type toward a more aerobic type. Specifically, it increases the proportion of type IIa muscle fibers, which are known for their fatigue resistance and dependence on oxidative metabolism.

Muscle Adaptations

The functional improvements in endurance and fiber type shift are supported by molecular changes in muscle tissue induced by SLU-PP-332:

• Activates ERRα-dependent exercise, just like a workout
• Significantly increases mitochondrial density and function in muscle fibers,
• Increases expression of GLUT4 glucose transporters, potentially increasing muscle's ability to uptake glucose during activity.
• It has also been suggested that increased blood vessel density in skeletal muscle would improve oxygen and nutrient delivery.

Importantly, these beneficial adaptations appear to occur without adverse effects. Levely serum creatine kinase, a marker of muscle damage, did not change significantly after using SLU-PP-332.

SLU-PP-332 in sports supplementation - when will it be useful?

Many people probably wonder what SLU-PP-332 can be used for in the case of training people? The supplement will perfectly support:

• Weight loss
• Endurance training
• Reducing stubborn fat
• Strength training
• Building aerobic capacity and base

Potential therapeutic applications of SLU-PP-332

Metabolic Diseases: Given its efficacy in reducing obesity, improving insulin sensitivity, increasing energy expenditure, and reducing fatty liver disease in animal models, SLU-PP-332 has significant potential in the treatment of obesity, metabolic syndrome, type 2 diabetes, and potentially nonalcoholic fatty liver disease (NASH).

Cardiovascular Disease: The demonstrated ability to improve cardiac function, reduce fibrosis, and increase survival in preclinical models of HF positions ERR agonists as a potential new therapeutic strategy for heart failure.

Age-Related Decline: Its ability to reverse age-related mitochondrial dysfunction, inflammation, and renal decline suggests potential in combating age-related kidney disease and perhaps other degenerative conditions associated with aging in which mitochondrial health is compromised.

Muscle Atrophy and Dysfunction: Exercise mimetic effects on muscle endurance and oxidative capacity suggest potential applications in conditions characterized by muscle atrophy, weakness, or fatigue, such as aging-related sarcopenia or specific muscle diseases. Although direct evidence for SLU-PP-332 in muscular dystrophy is limited in the material provided, ERRγ agonism has shown promising results in related contexts.

Neurodegenerative Diseases: Although SLU-PP-332 itself has poor brain penetration, the high expression of ERRs in the CNS and their association with mitochondrial function have sparked interest in developing brain-penetrating ERR agonists for potential use in Alzheimer's and Parkinson's diseases.

Summary - what is worth remembering?

SLU-PP-332 is a strong ERR agonist - which produces an effect similar to training. Its action creates beneficial metabolic changes and adaptations in muscles. In sports supplementation, it is an excellent support during the weight loss period. It will help maintain a high level of insulin sensitivity - increasing glucose uptake by muscles. Interestingly, SLU-PP-332 has many health-promoting properties, which in the future may be a valuable element supporting e.g. sacropenia, metabolic diseases, neurological degeneration.